姓名：鄧錫云

照片：

職稱：教授

職務(wù)：基礎(chǔ)醫(yī)學(xué)系主任、基礎(chǔ)醫(yī)學(xué)博士/碩士學(xué)位點(diǎn)負(fù)責(zé)人

研究生招生專業(yè)：基礎(chǔ)醫(yī)學(xué)（博士學(xué)位）；病理學(xué)與病理生理學(xué)（碩士學(xué)位）；腫瘤學(xué)（碩士學(xué)位）

聯(lián)系電話：0731-88912415（Office）

電子郵箱：dengxiyunmed@hunnu.edu.cn

簡(jiǎn)介：

鄧錫云博士，教授、博士生導(dǎo)師、湖南師范大學(xué)“世承人才”計(jì)劃入選者；現(xiàn)任湖南師范大學(xué)腫瘤干細(xì)胞與轉(zhuǎn)化醫(yī)學(xué)重點(diǎn)實(shí)驗(yàn)室主任、基礎(chǔ)醫(yī)學(xué)系主任兼博士/碩士學(xué)位點(diǎn)負(fù)責(zé)人。畢業(yè)于湘雅bwin必贏，在美國(guó)進(jìn)行博士后研究并獲得助理教授職位，于2012年全職引進(jìn)至bwin必贏。長(zhǎng)期從事腫瘤干細(xì)胞靶向藥物的研發(fā)及作用機(jī)制、代謝重編程和腫瘤轉(zhuǎn)移的分子機(jī)制等研究。率先提出用天然化合物針對(duì)三陰性乳腺癌干細(xì)胞進(jìn)行靶向治療；發(fā)現(xiàn)蛋白翻譯后修飾介導(dǎo)藥物誘導(dǎo)的腫瘤細(xì)胞應(yīng)激反應(yīng)并率先提出“反向核仁應(yīng)激”（reverse nucleolar stress）的概念。

主持國(guó)家自然科學(xué)基金面上項(xiàng)目5項(xiàng)以及湖南省自然科學(xué)基金、長(zhǎng)沙市科技項(xiàng)目、bwin必贏開放課題等多項(xiàng)科研課題；主編《Triple-Negative Breast Cancer（三陰性乳腺癌）》英文專著，由亞太地區(qū)規(guī)模最大的英文科技出版公司W(wǎng)orld Scientific Publishing出版；主編《Triple-Negative Breast Cancer》專刊1期；在Breast Cancer Research、InternationalJournal of Biological Sciences、Blood、Clinical Cancer Research、Cancer Treatment Reviews、ACS Applied Materials & Interfaces等高影響因子雜志發(fā)表科研論文或綜述100余篇。

主要研究方向：

1.三陰性乳腺癌干細(xì)胞靶向藥物的研發(fā)及作用機(jī)制

2.腫瘤微環(huán)境及代謝重編程

社會(huì)（學(xué)術(shù)）兼職：

1.腫瘤干細(xì)胞與轉(zhuǎn)化醫(yī)學(xué)校級(jí)重點(diǎn)實(shí)驗(yàn)室主任

2.Scientific Reports雜志編委

3.Journal of Cancer雜志編委

4.腫瘤藥學(xué)雜志編委

5.湖南師范大學(xué)學(xué)報(bào)（醫(yī)學(xué)版）常務(wù)編委

6.中國(guó)病理生理學(xué)會(huì)腫瘤專業(yè)委員會(huì)委員

7.湖南省解剖學(xué)會(huì)副理事長(zhǎng)

8.湖南省病理生理學(xué)會(huì)常務(wù)理事

9.湖南省病理生理學(xué)會(huì)腫瘤專業(yè)委員會(huì)副主任委員

10.中國(guó)抗癌協(xié)會(huì)會(huì)員

11.中國(guó)生物化學(xué)與分子生物學(xué)學(xué)會(huì)會(huì)員

獲得的人才項(xiàng)目（榮譽(yù)）：

湖南師范大學(xué)“世承人才”（2019年）

主持的科研項(xiàng)目：

（一）國(guó)家級(jí)項(xiàng)目

1.國(guó)家自然科學(xué)基金面上項(xiàng)目：核受體PXR在洛伐他汀促進(jìn)三陰性乳腺癌干細(xì)胞對(duì)多柔比星敏感性中的作用及機(jī)制

批準(zhǔn)號(hào)：82173374 起止日期：2022.01-2025.12 金額：55萬(wàn)元

2.國(guó)家自然科學(xué)基金面上項(xiàng)目：洛伐他汀通過(guò)核仁應(yīng)激介導(dǎo)的自噬抑制三陰性乳腺癌干細(xì)胞作用的分子機(jī)制

批準(zhǔn)號(hào)：81872167 起止日期：2019.01-2022.12 金額：58萬(wàn)元

3.國(guó)家自然科學(xué)基金面上項(xiàng)目：洛伐他汀靶向乳腺癌干細(xì)胞抑制EMT和轉(zhuǎn)移的作用及機(jī)制

批準(zhǔn)號(hào)：81472496 起止日期：2015.01-2018.12 金額：70萬(wàn)元

4.國(guó)家自然科學(xué)基金面上項(xiàng)目：EB病毒LMP1調(diào)節(jié)趨化因子受體CXCR4活性促進(jìn)鼻咽癌轉(zhuǎn)移的分子機(jī)制研究

批準(zhǔn)號(hào)：30771966 起止日期：2008.01-2010.12 金額：32萬(wàn)元

5.國(guó)家自然科學(xué)基金面上項(xiàng)目：趨化因子受體EBI1/CCR7在鼻咽癌轉(zhuǎn)移中的作用

批準(zhǔn)號(hào)：30170877 起止日期：2002.01-2003.12 金額：16萬(wàn)元

（二）省廳級(jí)項(xiàng)目

1.湖南省自然科學(xué)基金面上項(xiàng)目：洛伐他汀通過(guò)上調(diào)p14ARF促進(jìn)核仁應(yīng)激抑制三陰性乳腺癌干細(xì)胞作用的機(jī)制研究

批準(zhǔn)號(hào)：2019JJ40193 起止日期：2019.01-2021.12 金額：10萬(wàn)元

2.湖南省教育廳重點(diǎn)項(xiàng)目：莫那可林K靶向干細(xì)胞抑制乳腺癌轉(zhuǎn)移的實(shí)驗(yàn)研究

批準(zhǔn)號(hào)：14A089 起止日期：2014.09-2017.08 金額：6萬(wàn)元

（三）院校級(jí)項(xiàng)目

1.湖南師范大學(xué)優(yōu)秀回國(guó)人員科研啟動(dòng)基金：代謝調(diào)節(jié)分子AMPK在腫瘤轉(zhuǎn)移中的作用及機(jī)制研究

批準(zhǔn)號(hào)：130608 起止日期：2012.12-2022.11 金額：160萬(wàn)元

2.bwin必贏創(chuàng)新團(tuán)隊(duì)基金：基于腫瘤與生殖干細(xì)胞研究

批準(zhǔn)號(hào)：KF2022004 起止日期：2023.07-2024.06 金額：10萬(wàn)元

3.bwin必贏創(chuàng)新團(tuán)隊(duì)基金：腫瘤與生殖干細(xì)胞基礎(chǔ)與轉(zhuǎn)化研究

批準(zhǔn)號(hào)：KF2022002 起止日期：2022.07-2023.06 金額：16萬(wàn)元

代表性學(xué)術(shù)論文（#為并列第一作者，*為通訊作者)

1.Xiyun Deng, Hirotsugu Ueda, Shao Bo Su, Wanghua Gong, Nancy M. Dunlop, Ji-Liang Gao,Philip M. Murphy, Ji Ming Wang*. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R.Blood1999; 94(4):1165-1173.IF: 20.3

2.Jinyue Hu^#,Xiyun Deng^#, Xiuwu Bian, Guancheng Li, Yongqing Tong, Yuehui Li, Qingliang Wang, Rong Xin, Xiaojuan He, Guohua Zhou, Pingli Xie, Yanwen Li, Ji Ming Wang, Ya Cao*. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma.Clinical Cancer Research2005; 11(13):4658-4665.IF: 11.5

3.Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M Keller, Tao Yang*, Evan T Keller*. Recent Advances in Bone-Targeted Therapies of Metastatic Prostate Cancer.Cancer Treatment Reviews2014; 40(6):730-738.IF: 11.8

4.Xinyu Wang, Chanjuan Zheng, Hui Yao, Yuxuan Guo, Yian Wang, Guangchun He, Shujun Fu,Xiyun Deng*. Disulfidptosis: Six Riddles Necessitating Solutions.International Journal of Biological Sciences2024; 20(3):1042-1044.IF:9.2

5.Liujiang Song^#, Xiaojun Tao^#, Li Lin^#, Chao Chen, Hui Yao, Guangchun He, Guangyang Zou, Zhong Cao, Shichao Yan, Lu Lu, Huimei Yi, Di Wu, Siyuan Tan, Wanxin Ouyang, Zhifei Dai*,Xiyun Deng*. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells to Improve Therapeutic Efficacy.ACS Applied Materials & Interfaces2018; 10(8):7022-7030.IF: 8.9

6.Chanjuan Zheng#, Xi Xu#, Muyao Wu#, Lian Xue, Jianyu Zhu, Hongzhuo Xia, Siyu Ding, Shujun Fu, Xinyu Wang, Yian Wang, Guangchun He, Xia Liu*,Xiyun Deng*. Neutrophils in Triple-Negative Breast Cancer: An Underestimated Player with Increasingly Recognized Importance.Breast Cancer Research2023; 25(1):88.IF:7.3

7.Xiyun Deng*, Chanjuan Zheng, Faqing Tang, Thomas J Rosol, Zhi-Ming Shao*. Editorial: Triple-Negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy.Frontiers in Oncology2022; 12:1026566.

8.Sisi Chen, Ying Li, Muyao Wu, Lian Xue, Jianyu Zhu, Mi Wu, Qiuting Zhang, Guangchun He, Guifei Li, Shujun Fu, Chanjuan Zheng*,Xiyun Deng*. Nucleolar and Coiled-Body Phosphoprotein 1 (NOLC1) Is Associated with Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer.Frontiers in Oncology2022; 12:731528.

9.Mi Wu^#, Lu Lu^#, Sisi Chen, Ying Li, Qiuting Zhang, Shujun Fu*,Xiyun Deng*. Natural Products Inducing Nucleolar Stress: Implications in Cancer Therapy.Anticancer Drugs2022; 33(1):e21-e27.

10.Shichao Yan^#, Da Tang^#, Zhangyong Hong, Jing Wang, Hui Yao, Lu Lu, Huimei Yi, Shujun Fu, Chanjuan Zheng, Guangchun He, Heng Zou, Xuyang Hou, Qing He, Li Xiong*, Qinglong Li*,Xiyun Deng*. CD133 peptide-conjugated pyropheophorbide-a as a novel photosensitizer for targeted photodynamic therapy in colorectal cancer stem cells.Biomaterials Science2021; 9(6):2020-2031.IF: 6.6（封面文章）

11.Chanjuan Zheng^#, Shichao Yan^#, Lu Lu^#, Hui Yao, Guangchun He, Sisi Chen, Ying Li, Xiaojun Peng, Zhongyi Cheng, Mi Wu, Qiuting Zhang, Guifei Li, Shujun Fu,Xiyun Deng*. Lovastatin Inhibits EMT and MetastasisofTriple-Negative Breast Cancer Stem Cells ThroughDysregulation of Cytoskeleton-Associated Proteins.Frontiers in Oncology2021;11:656687.

12.Ying Li^#,Zhijun Zhan^#,Xuemin Yin,Shujun Fu*,Xiyun Deng*. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.Frontiers in Oncology2021;11:731535.

13.Huimei Yi^#, Ying Li^#,Yuan Tan^#, Shujun Fu*, Faqing Tang*,Xiyun Deng*. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.Frontiers in Oncology2021;11:648139.

14.Huimei Yi, Mi Wu, Qiuting Zhang, Lu Lu, Hui Yao, Sisi Chen, Ying Li, Chanjuan Zheng, Guangchun He,Xiyun Deng*. Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.Journal of Cancer2020; 11(13): 3713-3716.

15.Di Wu^#, Yao Chen^#, Shun Wen, Yi Wen, Rong Wang, Qiuting Zhang, Ge Qin, Huimei Yi, Mi Wu, Lu Lu, Xiaojun Tao*,Xiyun Deng*. Synergistically enhanced inhibitory effects of pullulan nanoparticle-mediated co-delivery of lovastatin and doxorubicin to triple-negative breast cancer cells.Nanoscale Research Letters2019; 14(1):314-325.

16.Liang Zeng,Xiyun Deng*, Jingmin Zhong, Li Yuan, Xiaojun Tao, Sai Zhang, Yong Zeng, Guangchun He, Pingping Tan, Yongguang Tao*. Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC Cancer2019; 9(1):831-841.

17.Lu Lu^#, Huimei Yi^#, Chao Chen^#, Shichao Yan, Hui Yao, Guangchun He, Guifei Li, Yiqun Jiang, Tuo Deng,Xiyun Deng*. Nucleolar stress: is there a reverse version?Journal of Cancer2018; 9(20): 3723-3727.

18.Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol,Xiyun Deng*. Triple-Negative Breast Cancer: Is There a Treatment on the Horizon?Oncotarget2017; 8(1):1913-1924.

19.Liang Zeng, Jingmin Zhong, Guangchun He, Fangjun Li, Jing Li, Wen Zhou, Wenbin Liu, Yun Zhang, Sanqian Huang, Zhihong Liu,Xiyun Deng*. Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.Journal of Cancer2017; 8(15):3062-3069.

20.Hui Yao, Guangchun He, Chao Chen, Shichao Yan, Lu Lu, Liujiang Song, K Vinod Vijayan, Qinglong Li, Li Xiong, Xiongying Miao,Xiyun Deng*. PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells.Journal of Cellular and Molecular Medicine2017; 21(9):2068-2076.IF: 5.3

21.Tao Yang, Hui Yao, Guangchun He, Liujiang Song, Ning Liu, Yan Wang, Yingke Yang, Evan T Keller,Xiyun Deng*. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis.Journal of Cancer2016; 7(2):192-199.

22.Xiyun Deng, Yanna Cao, Yan Liu, Fazhi Li, Kamalanathan Sambandam, Srinivasan Rajaraman, Archibald S Perkins, Alan P Fields, Mark R Hellmich, Courtney M Townsend Jr, E Aubrey Thompson, Tien C Ko*. Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.Molecular Carcinogenesis2013; 52(4):255-264.

23.Xiyun Deng*, Guangchun He, Andrea Levine, Ya Cao, Chad Mullins. Adenovirus-mediated Expression of TIMP-1 and TIMP-2 in Bone Inhibits the Growth of Human Prostate Cancer.International Journal of Cancer2008; 122(1):209-218.IF: 6.4

24.Xiyun Deng, Sarah H Tannehill-Gregg, Murali V P Nadella, Guangchun He, Andrea Levine, Ya Cao, Thomas J Rosol*. Parathyroid Hormone-related Protein and Ezrin Are Up-regulated in Human Lung Cancer Bone Metastases.Clinical & Experimental Metastasis2007; 24(2):107-119.

25.Xiyun Deng*, Sunita Bhagat, Zhong Dong, Chadwick Mullins, Sreenivasa Rao Chinni, Michael Cher. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.European Journal of Cancer2006; 42(18):3267-3273.IF: 8.4

26.Xiyun Deng, Min Kim, Didier Vandier, Yun-jin Jung, Toshiki Rikiyama, Magda K Sgagias, Merrill Goldsmith, Kenneth H Cowan*. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin.Biochemical & Biophysical Research Communications2002; 296(4):792-798.

科研獲獎(jiǎng)

湖南省自然科學(xué)獎(jiǎng)三等獎(jiǎng)項(xiàng)目名稱：洛伐他汀靶向乳腺癌干細(xì)胞的作用和機(jī)制研究。（完成人：鄧錫云、賀光春、姚慧、易慧媚、陸露、吳迪）

主編的專著及參編的書籍章節(jié)：

1.Xiyun Deng*, Faqing Tang*, Thomas J Rosol* (Editors):Triple-Negative Breast Cancer.Singapore: World Scientific Publishing, 2020 (ISBN 978-981-3277-75-5)

https://www.worldscientific.com/worldscibooks/10.1142/111990

微信推送：仁愛(ài)謹(jǐn)研，協(xié)同育人——我院鄧錫云教授出版三陰性乳腺癌《Triple-Negative Breast Cancer》專著 （bwin必贏 2021-10-04 23:41）

https://mp.weixin.qq.com/s/vRgyXPiCP-LUSxWnUBx1qA

2.Xiyun Deng*:Triple-negative breast cancer.InBreast Cancer.Berlin (Germany): Avid Science, 2016, pp. 1-33.

http://www.avidscience.com/wp-content/uploads/2016/06/BRSTC-16-01_June-03-2016.pdf

3.Xiyun Deng*, Jinlu Dai, Evan T Keller:Bone-targeted therapies of metastatic prostate cancer.InAdvances in Prostate Cancer.Berlin (Germany): Avid Science, 2016, pp. 1-47.

http://www.avidscience.com/wp-content/uploads/2017/01/RAPOC-15-01_Galley-Proof.pdf

4.陶永光、鄧錫云：核酸分析技術(shù)。曹亞主編：實(shí)用分子生物學(xué)操作指南人民衛(wèi)生出版社2003. pp. 70-129.

主編的SCI期刊?？?/strong>